Citation: | LIU Yi-hui, GUO Yan, FENG Hui, XU Hong, HAN Ying. Clinical observation of different hepatotoxic reactions of anti-tuberculosis drugs in the liver[J]. Chinese Journal of General Practice, 2022, 20(2): 240-242. doi: 10.16766/j.cnki.issn.1674-4152.002322 |
[1] |
中华医学会结核病学分会. 肺结核诊断和治疗指南[J]. 中华结核和呼吸杂志, 2001, 24(2): 70-74. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHJH200102001.htm
|
[2] |
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南[J]. 中华结核和呼吸杂志, 2019, 42(5): 343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
|
[3] |
中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11): 810-820. doi: 10.3760/cma.j.issn.1007-3418.2015.11.004
|
[4] |
林媛, 谭守勇, 彭德虎, 等. 抗结核治疗过程中出现药物性肝损伤对结核病疗效的影响[J]. 广州医药, 2019, 50(5): 15-20. doi: 10.3969/j.issn.1000-8535.2019.05.004
|
[5] |
祖大玲, 杨素云, 陈力. 获得性耐药肺结核危险因素分析及干预措施[J]. 蚌埠医学院学报, 2018, 43(8): 1109-1111. https://www.cnki.com.cn/Article/CJFDTOTAL-BANG201808043.htm
|
[6] |
SUN Q, ZHANG Q, GU J, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: A prospective cohort study[J]. Pharmacoepidemiolo Drug Saf, 2016, 25(8): 908-917. doi: 10.1002/pds.3988
|
[7] |
SONG J H, YOON S Y, PARK T Y, et al. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: A case control study[J]. Respir Res, 2019, 20(1): 283. doi: 10.1186/s12931-019-1256-y
|
[8] |
何涛, 汪峰, 唐武. 抗结核药致药物性肝损伤危险因素的logistic回归分析[J]. 中国药房, 2016, 27(12): 1626-1628. doi: 10.6039/j.issn.1001-0408.2016.12.15
|
[9] |
FENG F M, GUO M, CHEN Y, et al. Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury[J]. Genet Mol Rcs, 2014, 13(4): 9463-9471. doi: 10.4238/2014.November.11.11
|
[10] |
刘芳, 臧珊珊, 刘永梅, 等. 抗结核治疗致肺结核患者药物性肝损伤的危险因素分析[J]. 解放军医药杂志, 2019, 31(9): 56-59. doi: 10.3969/j.issn.2095-140X.2019.09.013
|
[11] |
李文红, 王芳, 付莹, 等. 肺结核药物性肝损害的相关因素分析[J]. 临床肺科杂志, 2016, 21(11): 2097-2100. doi: 10.3969/j.issn.1009-6663.2016.11.047
|
[12] |
何红迅. 肺结核患者药物性肝损伤的影响因素分析[J]. 临床医学工程, 2020, 27(7): 979-980. doi: 10.3969/j.issn.1674-4659.2020.07.0979
|
[13] |
刘国华. 抗结核药物所致药物性肝损害的临床分析[J]. 中国现代医生, 2020, 58(10): 107-109. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202010030.htm
|
[14] |
ZHAO H, WANG Y, ZHANG T, et al. Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study[J]. Med Sci Monit, 2020, 26: e920350.
|
[15] |
陈诗娴, 周玲, 陈永忠, 等. 住院抗结核治疗患者药物性肝炎发生及转归研究[J]. 中华流行病学杂志, 2016, 37(7): 930-934. doi: 10.3760/cma.j.issn.0254-6450.2016.07.005
|
[16] |
AITHAL G P, WATKINS P B, ANDRADE R J, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmaeol Ther, 2011, 89(6): 806-815. doi: 10.1038/clpt.2011.58
|
[17] |
徐张巍, 李杨, 许建明. 抗结核药物性肝损伤适应现象的临床研究[J]. 中华肝脏病杂志, 2013, 21(9): 697-700. doi: 10.3760/cma.j.issn.1007-3418.2013.09.012
|